893739-89-4

Basic information

• Product Name: 4-CYCLOPROPYL-2-FLUOROANILINE
• Synonyms: AKOS BAR-1302;4-CYCLOPROPYL-2-FLUOROANILINE;4-Cyclopropyl-2-fluorophenylamine
• CAS NO: 893739-89-4
• Molecular Formula: C₉H₁₀FN
• Molecular Weight: 151.18
• Mol File: 893739-89-4.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-CYCLOPROPYL-2-FLUOROANILINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-CYCLOPROPYL-2-FLUOROANILINE(893739-89-4)
• EPA Substance Registry System: 4-CYCLOPROPYL-2-FLUOROANILINE(893739-89-4)

Safety Data

• Hazardous Substances Data: 893739-89-4(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Cyclopropyl-2-fluoroaniline is used as a key intermediate in the synthesis of arylamide derivatives, which serve as RAF/MEK complex stabilizers and/or MEK inhibitors. These compounds play a crucial role in the development of targeted antitumor agents, as they can modulate the activity of the RAF/MEK/ERK signaling pathway, which is often dysregulated in cancer cells.
Additionally, 4-cyclopropyl-2-fluoroaniline can be utilized in the design and synthesis of novel MEK inhibitors, which are potential therapeutic agents for the treatment of various cancers. By inhibiting MEK, these compounds can disrupt the signaling cascade that promotes cell proliferation and survival, thereby exhibiting antitumor activity.

Upstream product

• 367-24-8 4-bromo-2-fluoroaniline 
• 411235-57-9 cyclopropylboronic acid 
• 932700-92-0 4-cyclopropyl-2-fluoro-1-nitrobenzene 
• 144-55-8 sodium hydrogencarbonate 
• 256935-94-1 trifluoromethanesulfonic acid 3-fluoro-4-nitrophenyl ester 
• 394-41-2 3-fluoro-4-nitrophenol 

Downstream Products

• 1030383-32-4 4-cyclopropyl-2-fluoro-1-iodobenzene 
• 1168091-05-1 5-(2-fluoro-4-cyclopropylphenylamino)-imidazo[1,5-a]pyridine-6-carboxylic acid methyl ester 
• 1168102-38-2 8-(4-cyclopropyl-2-fluorophenylamino)-imidazo[1,5-a]pyridine-7-carboxylic acid methyl ester 
• 1203662-87-6 7-(4-cyclopropyl-2-fluoro-phenylamino)-benzo[d]isothiazole-6-carboxylic acid 

Relevant articles and documents

OXEPAN-2-YL-PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Oxepan-2-yl pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for in

CYCLIC ETHER PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Cyclic ether pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein R2 is a cyclic ether and X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is thiazolyl, pyrazinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PYRAZOL-4-YL-HETEROCYCLYL-CARBOXAMIDE COMPOUNDS AND METHODS OF USE

Pyrazol-4-yl-heterocyclyl-carboxamide compounds of Formula I, including stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof, wherein X is a thiazolyl, picolinyl, pyridinyl, or pyrimidinyl, are useful for inhibiting Pim kinase, and for treating disorders such as cancer mediated by Pim kinase. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

BICYCLIC HETEROCYCLES AS MEK KINASE INHIBITORS

The invention relates to bicyclic heterocycles of formulae I and II with anti-cancer and/or anti-inflammatory activity and more specifically with MEK kinase inhibitory activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth, treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

5-ANILINOIMIDAZOPYRIDINES AND METHODS OF USE

The invention relates to imidazopyridines of formula I with anti-cancer and/or anti-inflammatory activity and more specifically to imidazopyridines which inhibit MEK kinase activity. The invention provides compositions and methods useful for inhibiting abnormal cell growth or treating a hyperproliferative disorder, or treating an inflammatory disease in a mammal. The invention also relates to methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

METHOD FOR INHIBITING PROLIFERATION OF TUMOR CELLS

Disclosed are methods for synergistically inhibiting the proliferation of tumor cells by contacting the tumor cells with a MEK inhibitor compound and erlotinib, either sequentially or simultaneously. Also disclosed are methods for inhibiting the proliferation of tumor cells in a human, by administering to the human, sequentially or simultaneously, an amount of erlotinib and a MEK inhibitor compound, wherein the amounts are effective, in combination, to synergistically inhibit the proliferation of the tumor cells in the human.

Substituted hydantoins

The present invention relates to compounds of the formula methods for the preparation thereof, and methods for their use. The compounds are useful in treating diseases characterized by the hyperactivity of MEK. Accordingly the compounds are useful in the treatment of diseases, such as cancer, cognitive and CNS disorders, and inflammatory/autoimmune diseases.

SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS

Compounds of formula (I) wherein R is hydrogen, lower alkyl, (C3-C8)cycloalkyl, hydroxy, halo, lower alkoxy, trifluoromethoxy, trifluoromethyl or cyano; and A is biaryl, optionally substituted β-naphthyl, bicyclic heterocyclic aryl, (C3-C6)cycloalkylmonocyclic carbocyclic aryl, or (C5 or C6)cycloalkane fused-monocyclic carbocyclic aryl; pharmaceutically acceptable salts thereof, and pharmaceutically acceptable esters thereof; which are useful for the treatment of COX-2 dependent disorders.